Search Results - "O’Hara, Mark H."

Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers by Haas, Andrew R., Tanyi, Janos L., O’Hara, Mark H., Gladney, Whitney L., Lacey, Simon F., Torigian, Drew A., Soulen, Michael C., Tian, Lifeng, McGarvey, Maureen, Nelson, Anne Marie, Farabaugh, Caitlin S., Moon, Edmund, Levine, Bruce L., Melenhorst, J. Joseph, Plesa, Gabriela, June, Carl H., Albelda, Steven M., Beatty, Gregory L.

“…This phase I study investigated the safety and activity of lentiviral-transduced chimeric antigen receptor (CAR)-modified autologous T cells redirected against…”
Get full text

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial by Padrón, Lacey J., Maurer, Deena M., O’Hara, Mark H., O’Reilly, Eileen M., Wolff, Robert A., Wainberg, Zev A., Ko, Andrew H., Fisher, George, Rahma, Osama, Lyman, Jaclyn P., Cabanski, Christopher R., Yu, Jia Xin, Pfeiffer, Shannon M., Spasic, Marko, Xu, Jingying, Gherardini, Pier Federico, Karakunnel, Joyson, Mick, Rosemarie, Alanio, Cécile, Byrne, Katelyn T., Hollmann, Travis J., Moore, Jonni S., Jones, Derek D., Tognetti, Marco, Chen, Richard O., Yang, Xiaodong, Salvador, Lisa, Wherry, E. John, Dugan, Ute, O’Donnell-Tormey, Jill, Butterfield, Lisa H., Hubbard-Lucey, Vanessa M., Ibrahim, Ramy, Fairchild, Justin, Bucktrout, Samantha, LaVallee, Theresa M., Vonderheide, Robert H.

“…Chemotherapy combined with immunotherapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for pancreatic ductal…”
Get full text

Hepatocytes direct the formation of a pro-metastatic niche in the liver by Lee, Jae W., Stone, Meredith L., Porrett, Paige M., Thomas, Stacy K., Komar, Chad A., Li, Joey H., Delman, Devora, Graham, Kathleen, Gladney, Whitney L., Hua, Xia, Black, Taylor A., Chien, Austin L., Majmundar, Krishna S., Thompson, Jeffrey C., Yee, Stephanie S., O’Hara, Mark H., Aggarwal, Charu, Xin, Dong, Shaked, Abraham, Gao, Mingming, Liu, Dexi, Borad, Mitesh J., Ramanathan, Ramesh K., Carpenter, Erica L., Ji, Ailing, de Beer, Maria C., de Beer, Frederick C., Webb, Nancy R., Beatty, Gregory L.

“…The liver is the most common site of metastatic disease 1 . Although this metastatic tropism may reflect the mechanical trapping of circulating tumour cells,…”
Get full text

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial by Beatty, Gregory L., O’Hara, Mark H., Lacey, Simon F., Torigian, Drew A., Nazimuddin, Farzana, Chen, Fang, Kulikovskaya, Irina M., Soulen, Michael C., McGarvey, Maureen, Nelson, Anne Marie, Gladney, Whitney L., Levine, Bruce L., Melenhorst, J. Joseph, Plesa, Gabriela, June, Carl H.

“…Pancreatic ductal adenocarcinoma (PDAC) is resistant to T-cell–mediated immunotherapy. We engineered T cells to transiently express a messenger RNA encoding a…”
Get full text

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting by Bear, Adham S., Blanchard, Tatiana, Cesare, Joseph, Ford, Michael J., Richman, Lee P., Xu, Chong, Baroja, Miren L., McCuaig, Sarah, Costeas, Christina, Gabunia, Khatuna, Scholler, John, Posey, Avery D., O’Hara, Mark H., Smole, Anze, Powell, Daniel J., Garcia, Benjamin A., Vonderheide, Robert H., Linette, Gerald P., Carreno, Beatriz M.

“…Activating RAS missense mutations are among the most prevalent genomic alterations observed in human cancers and drive oncogenesis in the three most lethal…”
Get full text

An NK-like CAR T cell transition in CAR T cell dysfunction by Good, Charly R., Aznar, M. Angela, Kuramitsu, Shunichiro, Samareh, Parisa, Agarwal, Sangya, Donahue, Greg, Ishiyama, Kenichi, Wellhausen, Nils, Rennels, Austin K., Ma, Yujie, Tian, Lifeng, Guedan, Sonia, Alexander, Katherine A., Zhang, Zhen, Rommel, Philipp C., Singh, Nathan, Glastad, Karl M., Richardson, Max W., Watanabe, Keisuke, Tanyi, Janos L., O’Hara, Mark H., Ruella, Marco, Lacey, Simon F., Moon, Edmund K., Schuster, Stephen J., Albelda, Steven M., Lanier, Lewis L., Young, Regina M., Berger, Shelley L., June, Carl H.

“…Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies but remains ineffective in solid tumors, due in…”
Get full text

Challenges and Opportunities for Pancreatic Cancer Immunotherapy by Bear, Adham S., Vonderheide, Robert H., O'Hara, Mark H.

“…Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types. Its unique genomic landscape shaped by oncogenic drivers promotes immune…”
Get full text

Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma by Till, Jacob E., McDaniel, Lee, Chang, Changgee, Long, Qi, Pfeiffer, Shannon M., Lyman, Jaclyn P., Padrón, Lacey J., Maurer, Deena M., Yu, Jia Xin, Spencer, Christine N., Gherardini, Pier Federico, Da Silva, Diane M., LaVallee, Theresa M., Abbott, Charles, Chen, Richard O., Boyle, Sean M., Bhagwat, Neha, Cannas, Samuele, Sagreiya, Hersh, Li, Wenrui, Yee, Stephanie S., Abdalla, Aseel, Wang, Zhuoyang, Yin, Melinda, Ballinger, Dominique, Wissel, Paul, Eads, Jennifer, Karasic, Thomas, Schneider, Charles, O’Dwyer, Peter, Teitelbaum, Ursina, Reiss, Kim A., Rahma, Osama E., Fisher, George A., Ko, Andrew H., Wainberg, Zev A., Wolff, Robert A., O’Reilly, Eileen M., O’Hara, Mark H., Cabanski, Christopher R., Vonderheide, Robert H., Carpenter, Erica L.

“…While high circulating tumor DNA (ctDNA) levels are associated with poor survival for multiple cancers, variant-specific differences in the association of…”
Get full text

A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma by Yang, Zijian, LaRiviere, Michael J, Ko, Jina, Till, Jacob E, Christensen, Theresa, Yee, Stephanie S, Black, Taylor A, Tien, Kyle, Lin, Andrew, Shen, Hanfei, Bhagwat, Neha, Herman, Daniel, Adallah, Andrew, O'Hara, Mark H, Vollmer, Charles M, Katona, Bryson W, Stanger, Ben Z, Issadore, David, Carpenter, Erica L

“…To determine whether a multianalyte liquid biopsy can improve the detection and staging of pancreatic ductal adenocarcinoma (PDAC). We analyzed plasma from 204…”
Get full text

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib by Brown, Timothy J, Yablonovitch, Arielle, Till, Jacob E, Yen, Jennifer, Kiedrowski, Lesli A, Hood, Ryan, O'Hara, Mark H, Teitelbaum, Ursina, Karasic, Thomas B, Schneider, Charles, Carpenter, Erica L, Nathanson, Katherine, Domchek, Susan M, Reiss, Kim A

“…PARP inhibitors (PARPi) provide an effective maintenance option for patients with BRCA- or PALB2-mutated pancreatic cancer. However, mechanisms of PARPi…”
Get full text

Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer by Ko, Andrew H., Jordan, Alexander C., Tooker, Evan, Lacey, Simon F., Chang, Renee B., Li, Yan, Venook, Alan P., Tempero, Margaret, Damon, Lloyd, Fong, Lawrence, O’Hara, Mark H., Levine, Bruce L., Melenhorst, J. Joseph, Plesa, Gabriela, June, Carl H., Beatty, Gregory L.

“…B cells infiltrate pancreatic ductal adenocarcinoma (PDAC) and in preclinical cancer models, can suppress T cell immunosurveillance in cancer. Here, we…”
Get full text

Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors by Bear, Adham S, Nadler, Rebecca B, O'Hara, Mark H, Stanton, Kelsey L, Xu, Chong, Saporito, Robert J, Rech, Andrew J, Baroja, Miren L, Blanchard, Tatiana, Elliott, Maxwell H, Ford, Michael J, Jones, Richard C, Patel, Shivang, Brennan, Andrea L, O'Neil, Zachary, Powell, Jr, Daniel J, Vonderheide, Robert H, Linette, Gerald P, Carreno, Beatriz M

“…Neoantigens derived from KRASMUT have been described, but the fine antigen specificity of T cell responses directed against these epitopes are poorly…”
Get full text

Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer by Ben-Ami, Roni, Wang, Qiao-Li, Zhang, Jinming, Supplee, Julianna G, Fahrmann, Johannes F, Lehmann-Werman, Roni, Brais, Lauren K, Nowak, Jonathan, Yuan, Chen, Loftus, Maureen, Babic, Ana, Irajizad, Ehsan, Davidi, Tal, Zick, Aviad, Hubert, Ayala, Neiman, Daniel, Piyanzin, Sheina, Gal-Rosenberg, Ofer, Horn, Amit, Shemer, Ruth, Glaser, Benjamin, Boos, Natalia, Jajoo, Kunal, Lee, Linda, Clancy, Thomas E, Rubinson, Douglas A, Ng, Kimmie, Chabot, John A, Kastrinos, Fay, Kluger, Michael, Aguirre, Andrew J, Jänne, Pasi A, Bardeesy, Nabeel, Stanger, Ben, O'Hara, Mark H, Till, Jacob, Maitra, Anirban, Carpenter, Erica L, Bullock, Andrea J, Genkinger, Jeanine, Hanash, Samir M, Paweletz, Cloud P, Dor, Yuval, Wolpin, Brian M

“…Pancreatic ductal adenocarcinoma (PDAC) is commonly diagnosed at an advanced stage. Liquid biopsy approaches may facilitate detection of early stage PDAC when…”
Get more information

Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART) by Flynn, James P., O’Hara, Mark H., Gandhi, Saumil J.

“…An increasing appreciation for the role of the immune system in targeting cancer cells over the last decade has led to the development of several…”
Get full text

Molecular Triage Trials in Colorectal Cancer by O'Hara, Mark H, Hamilton, Stanley R, O'Dwyer, Peter J

“…Advances in the understanding of genomic alterations in cancer, and the various therapies targeted to these alterations have permitted the design of trials…”
Get full text

Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1 , BRCA2 , or PALB2 by Reiss, Kim A, Mick, Rosemarie, O'Hara, Mark H, Teitelbaum, Ursina, Karasic, Thomas B, Schneider, Charles, Cowden, Stacy, Southwell, Traci, Romeo, Janae, Izgur, Natallia, Hannan, Zain M, Tondon, Rashmi, Nathanson, Katherine, Vonderheide, Robert H, Wattenberg, Max M, Beatty, Gregory, Domchek, Susan M

“…Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and a…”
Get full text

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study by O'Hara, Mark H, O'Reilly, Eileen M, Varadhachary, Gauri, Wolff, Robert A, Wainberg, Zev A, Ko, Andrew H, Fisher, George, Rahma, Osama, Lyman, Jaclyn P, Cabanski, Christopher R, Mick, Rosemarie, Gherardini, Pier Federico, Kitch, Lacey J, Xu, Jingying, Samuel, Theresa, Karakunnel, Joyson, Fairchild, Justin, Bucktrout, Samantha, LaVallee, Theresa M, Selinsky, Cheryl, Till, Jacob E, Carpenter, Erica L, Alanio, Cécile, Byrne, Katelyn T, Chen, Richard O, Trifan, Ovid C, Dugan, Ute, Horak, Christine, Hubbard-Lucey, Vanessa M, Wherry, E John, Ibrahim, Ramy, Vonderheide, Robert H

“…Standard chemotherapy remains inadequate in metastatic pancreatic adenocarcinoma. Combining an agonistic CD40 monoclonal antibody with chemotherapy induces…”
Get full text

Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial by Karasic, Thomas B, O'Hara, Mark H, Loaiza-Bonilla, Arturo, Reiss, Kim A, Teitelbaum, Ursina R, Borazanci, Erkut, De Jesus-Acosta, Ana, Redlinger, Colleen, Burrell, Jessica A, Laheru, Daniel A, Von Hoff, Daniel D, Amaravadi, Ravi K, Drebin, Jeffrey A, O'Dwyer, Peter J

“…Autophagy is a mechanism of treatment resistance to chemotherapy that has a role in the maintenance of pancreatic cancer. Hydroxychloroquine sulfate (HCQ) is…”
Get more information

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer by Byrne, Katelyn T, Betts, Courtney B, Mick, Rosemarie, Sivagnanam, Shamilene, Bajor, David L, Laheru, Daniel A, Chiorean, E Gabriela, O'Hara, Mark H, Liudahl, Shannon M, Newcomb, Craig, Alanio, Cécile, Ferreira, Ana P, Park, Byung S, Ohtani, Takuya, Huffman, Austin P, Väyrynen, Sara A, Dias Costa, Andressa, Kaiser, Judith C, Lacroix, Andreanne M, Redlinger, Colleen, Stern, Martin, Nowak, Jonathan A, Wherry, E John, Cheever, Martin A, Wolpin, Brian M, Furth, Emma E, Jaffee, Elizabeth M, Coussens, Lisa M, Vonderheide, Robert H

“…CD40 activation is a novel clinical opportunity for cancer immunotherapy. Despite numerous active clinical trials with agonistic CD40 monoclonal antibodies…”
Get full text

Early treatment-related neutropenia predicts response to palbociclib by McAndrew, Nicholas P., Dickson, Mark A., Clark, Amy S., Troxel, Andrea B., O’Hara, Mark H., Colameco, Christopher, Gallager, Maryann, Gramlich, Kristi, Zafman, Kelly, Vaughn, David, Schwartz, Gary K., O’Dwyer, Peter J., DeMichele, Angela

“…Background Palbociclib is highly active in oestrogen-receptor positive (ER+) metastatic breast cancer, but neutropenia is dose limiting. The goal of this study…”
Get full text